Breaking News on Global Pharmaceutical Technology & Manufacturing

Berlex buys CompleGen system

09-Apr-2003

Related topics: Processing

Genetics-based drug discovery company CompleGen is to supply Berlex Biosciences , a US affiliate of German company Schering, with a high throughput assay system for discovery of compounds active against a novel target identified by Berlex.

Announcing the agreement this week the two companies said that Berlex has paid CompleGen a fee, with further terms and payments to be agreed if suitable compounds, identified during the project, are developed and commercialised.

 

The target assay uses CompleGen's XenoGene system which identifies compounds that are specifically active against the target protein, but not other cellular components.

 

"We are very happy to be working with Berlex' Oncology Research group and their skilled compound screening team," said Dr John Swindle, CompleGen's chief scientific officer.

 

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.